Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

The purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were HER2-negative by standard tests but showed abnormal HER2 activity based on the CELsignia results.

Trial Details

NCT ID
NCT04965064
Phase
PHASE2
Sponsor
University of Rochester
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Capecitabine and Neratinib.
Locations (sample)
  • Rochester, New York, United States|43.15478,-77.61556

Key Eligibility Criteria

  • Subjects must meet all of the following criteria to be enrolled:
  • Male/Female
  • At least 18 years of age
  • Histologically confirmed HER2 negative breast cancer determined from the most recent tumor sample (primary or metastatic), as per the current Ameri…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →